Experimental vaccine trains immune system to attack deadly brain cancer
NCT ID NCT06342908
First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This early-phase trial tests a personalized vaccine made from a patient's own white blood cells to treat a rare and aggressive brain tumor called H3 G34-mutant diffuse hemispheric glioma. The vaccine is designed to help the immune system recognize and kill tumor cells. Six adults aged 18-50 will receive the vaccine to see if it is safe and feasible, with researchers monitoring side effects and immune response.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- personalized dendritic cell vaccine (made from the patient's own white blood cells)
- What this could lead to
- If it works, this could point toward a new way to train the immune system to fight this rare and aggressive brain tumor.
- What could go wrong
- This is a very early, small trial with only 6 participants. The vaccine may not trigger a strong enough immune response or could cause side effects. Success in this phase does not guarantee effectiveness.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for DIFFUSE HEMISPHERIC GLIOMA, H3 G34-MUTANT are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
UCLA / Jonsson Comprehensive Cancer Center
Los Angeles, California, 90095, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.